Evaluation of the Safety and Tolerability of AC01 in Patients with Heart Failure

The primary objective of the study is to evaluate the **safety** and **tolerability** of AC01 in patients diagnosed with **heart failure**. This is clinically relevant as heart failure is a prevalent condition that significantly impacts patient morbidity and mortality. Understanding the safety profile of AC01 is crucial for determining its potential as a therapeutic option in this patient population.

The clinical trial involves a total of **16 participants** diagnosed with **Heart Failure**. The study population includes both male and female subjects, with an age range that spans from young adults to older adults. Participants were selected to include a vulnerable population, ensuring a comprehensive understanding of the condition across different demographics. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process aimed to encompass a diverse group, although specific inclusion or exclusion criteria were not provided by the sponsor.

The clinical trial is designed to evaluate the **safety** and tolerability of AC01 in patients diagnosed with **heart failure**. The study follows a randomized, double-blind, controlled trial design, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence recruitment on October 17, 2022, and is projected to conclude by December 31, 2025, providing a comprehensive assessment over an extended period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This initial visit is crucial for determining participant suitability for the trial. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor their health status, adherence to the study protocol, and any adverse events. These visits are integral to ensuring participant safety and the collection of consistent data throughout the trial duration. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather concluding data on the treatment's effects.

The expected length of participant involvement spans the entire trial duration, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. These measures are in place to prioritize participant safety and maintain the integrity of the trial data.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to conclude by December 31, 2025, with recruitment having commenced on October 17, 2022. The trial is categorized under phase 9, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation. The trial's advanced phase implies a robust framework for efficacy assessment, ensuring that the collected data will contribute to a thorough understanding of the treatment's effectiveness.